Journal Article

Immune Checkpoint Inhibitors in Prostate Cancer

McFarland, Taylor R., Agarwal, Neeraj, Swami, Umang, Venkatachalam, Shobi

2021

Overview

Metastatic prostate cancer is a lethal disease with limited treatment options. Immune checkpoint inhibitors have dramatically changed the treatment landscape of multiple cancer types but have met with limited success in prostate cancer. In this review, we discuss the preclinical studies providing the rationale for the use of immunotherapy in prostate cancer and underlying biological barriers inhibiting their activity. We discuss the predictors of response to immunotherapy in prostate cancer. We summarize studies evaluating immune checkpoint inhibitors either as a single agent or in combination with other checkpoint inhibitors or with other agents such as inhibitors of androgen axis, poly ADP-ribose polymerase (PARP), radium-223, radiotherapy, cryotherapy, tumor vaccines, chemotherapy, tyrosine kinase inhibitors, and granulocyte-macrophage colony-stimulating factor. We thereafter review future directions including the combination of immune checkpoint blockade with inhibitors of adenosine axis, bispecific T cell engagers, PSMA directed therapies, adoptive T-cell therapy, and multiple other miscellaneous agents.

• Publisher: MDPI AG,MDPI
• Subject: Adenosine / Androgens / c-Met protein / Cancer therapies / Cancer vaccines / Cell therapy / Chemotherapy / Clinical trials / Colony-stimulating factor / Cryotherapy / Cyclin-dependent kinases / Cytotoxicity / DNA repair / Granulocyte-macrophage colony-stimulating factor / Hypoxia / Immune checkpoint inhibitors / Immune system / Immunotherapy / Kinases / Ligands / Lung cancer / Lymphocytes / Lymphocytes T / Melanoma / Metastases / Metastasis / Mutation / Poly(ADP-ribose) polymerase / Prostate cancer / Protein-tyrosine kinase / Radiation therapy / Radium / Review / Reviews / Ribose